Stock Taper
SCREENER COMPARE ANY 2 STOCKS
ERAS
ERASCA, INC.
NASDAQ
$18.03
▼ DOWN 7.49% (-1.46)

KEY STATISTICS

Market Cap$6.26 B
52w High$24.28
52w Low$1.33
Dividend Yield—
Frequency—
P/E-19.39
Volume2.89M
Shares Out.347.13M

COMPANY

LEADERSHIP

Jonathan E. Lim
CHIEF EXECUTIVE
Jonathan E. Lim

COMPENSATION 2026

Salary$670,400
Stock Awards$0
Incentive Plan Pay$482,688
All Other Comp.$10,500
Total$4,298,838

ABOUT

SECTOR
Healthcare
WENT PUBLIC
July 16, 2021
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
103

PRICE TARGET

Target High$30.00
Target Low$16.00
Target Median$21.50
Target Consensus$22.50

UPCOMING EARNINGS

DateNov 11, 2026
DayWednesday
Rev. Est.—
NOV
11
WED

PRICE

$18.03 ▼ DOWN 7.49% (−$1.46)
$18.00$18.50$19.00$19.509:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM18.03

About Erasca, Inc.

https://www.erasca.com ↗

Erasca, Inc. is a clinical-stage biopharmaceutical company developing therapies targeting RAS/MAPK-driven cancers, including ERK1/2, SHP2, and EGFR inhibitors for various solid tumors and CNS cancers.

INDUSTRY

Biotechnology

A PRODUCT ERASCA, INC. IS KNOWN FOR

ERAS-0015
ERAS-0015

ERAS-0015 is an investigational oral molecular glue targeting RAS mutations, showing promising early results in its AURORAS-1 Phase 1 trial across multiple cancer types.

COMPETITORS

COMPETITOR
BBIO COMPARE
BMY COMPARE
KURA COMPARE
RLAY COMPARE
RVMD COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
142
LISTED HERE
26
RANKED BY POSITION SIZE
VTI
0.01% · 9.8M
XBI
1.30% · 7.9M
XSU.TO
0.12% · 5.6M
SCHA
0.11% · 1.3M
TCAF
0.24% · 1.0M
FESM
0.14% · 462.1K
PTH
2.78% · 416.8K
DFAC
0.02% · 402.6K
LABU
0.88% · 287.9K
XRSG.L
0.13% · 215.3K
USVM
0.22% · 213.5K
CANC
1.77% · 208.2K
RSSL
0.13% · 105.2K
BBSC
0.15% · 62.7K
GSSC
0.10% · 53.7K
FSCC
0.27% · 51.9K
BBC
0.83% · 22.3K
RTWO.L
0.19% · 21.8K
BIB
0.20% · 11.1K
STXK
0.20% · 9.4K
BKSE
0.16% · 8.2K
RFLR
0.11% · 5.7K
ESSC
0.27% · 5.5K
VETS
0.13% · 3.9K
USFMDN.MX
0.01% · 895
AVIE
0.07% · 450

INSTITUTIONAL OWNERSHIP

SHARES OWNED
56.34%
HOLDERS
317
TOP 12 OF 317 · RANKED BY POSITION SIZE
Frazier Life Sciences Management, L.P.
25.0M sh · $457.55M
T. Rowe Price Investment Management, Inc.
21.3M sh · $343.98M
Blackrock, Inc.
21.2M sh · $387.54M
Rtw Investments, LP
17.9M sh · $328.78M
Vr Adviser, LLC
17.9M sh · $327.78M
Logos Global Management LP
15.2M sh · $33.03M
Suvretta Capital Management, LLC
14.5M sh · $53.95M
Paradigm Biocapital Advisors LP
14.2M sh · $52.67M
Vanguard Group Inc
12.8M sh · $47.66M
State Street Corp
12.2M sh · $223.22M
Vivo Capital, LLC
12.2M sh · $196.61M
Siren, L.L.C.
11.4M sh · $208.81M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
Fuchs Charles S.
— · —
2026-08-10
★
OFFICER: PRESIDENT, R&D
Fuchs Charles S.
Purchase · 1.3M shares
2026-08-10
★
DIRECTOR
Multani Pratik S
Purchase · 29.9K shares
2026-06-26
★
DIRECTOR
Hambleton Julie
Purchase · 29.9K shares
2026-06-26

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 4
OVERWEIGHT 2
NEUTRAL 1
EQUAL WEIGHT 1
OUTPERFORM 1
9 GRADES IN THE LAST 12 MONTHS
B of A Securities NEUTRAL Guggenheim BUY HC Wainwright & Co. BUY Morgan Stanley EQUAL WEIGHT Mizuho OUTPERFORM Stifel BUY JP Morgan OVERWEIGHT Piper Sandler OVERWEIGHT

SECTORS PEERS

PEERPRICE
IOVA$8.01COMPARE
MBX$63.00COMPARE
AVBP$30.17COMPARE
MGTX$13.82COMPARE
MLTX$14.99COMPARE
CRVS$14.16COMPARE
CTMX$3.21COMPARE
VALN$6.43COMPARE